One-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age Hans-Peter SchwarzDorota Birkholz-WalerzakEllen Schuck Original Research Open access 28 January 2014 Pages: 1 - 13
Isoagglutinin Reduction in Human Immunoglobulin Products by Donor Screening Brigitte SianiKatharina WillimannEleonora Widmer Original Research Open access 20 May 2014 Pages: 15 - 26
Switching to Omnitrope® from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System Nazia RashidPaul SaengerRobert Rapaport Original Research Open access 06 August 2014 Pages: 27 - 39
Enhancing Patient Flexibility of Subcutaneous Immunoglobulin G Dosing: Pharmacokinetic Outcomes of Various Maintenance and Loading Regimens in the Treatment of Primary Immunodeficiency Jagdev SidhuMikhail RojavinJonathan Edelman Original Research Open access 14 August 2014 Pages: 41 - 55
Healthcare Resource Utilization in Patients Receiving Omalizumab for Allergic Asthma in a Real-World Setting Gert-Jan BraunstahlJanice CanvinPanayiotis Georgiou Original Research Open access 05 November 2014 Pages: 57 - 67
To the Editor; A Commentary on “Switching From Originator to Biosimilar Human Growth Hormone Using a Dialogue Teamwork: Single-Center Experience From Sweden” Mats EkelundChristopher BidadRoy Gomez Commentary Open access 23 April 2014 Pages: 69 - 71
Weekly Teriparatide for Delayed Unions of Atypical Subtrochanteric Femur Fractures Fumio FukudaNaoaki KurinomaruAkihiko Hijioka Case Report Open access 29 January 2014 Pages: 73 - 79
Erratum to: Switching to Omnitrope® from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System Nazia RashidPaul SaengerRobert Rapaport Erratum Open access 19 November 2014 Pages: 81 - 81